TG Therapeutics Phase 3 ENHANCE trial meets primary endpoint for simplified BRIUMVI dosing

TG Therapeutics announced positive Phase 3 results showing bioequivalent drug exposure between a new single 600mg Day 1 infusion versus the current two-infusion regimen for BRIUMVI in multiple sclerosis patients. The company plans to file a supplemental BLA in 2H-2026, potentially positioning BRIUMVI as the first IV anti-CD20 requiring only a single initiation infusion.